Surgical Science Sweden AB (SUS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Surgical Science Sweden AB (SUS) has a cash flow conversion efficiency ratio of -0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-4.37 Million ≈ $-470.07K USD) by net assets (Skr4.30 Billion ≈ $462.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Surgical Science Sweden AB - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Surgical Science Sweden AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SUS current and long-term liabilities for a breakdown of total debt and financial obligations.
Surgical Science Sweden AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Surgical Science Sweden AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Spurcorp
JSE:SUR
|
0.257x |
|
McKinley Acquisition Corporation Class A Ordinary Shares
NASDAQ:MKLY
|
-0.001x |
|
M-tron Industries, Inc.
NYSE MKT:MPTI
|
0.095x |
|
Tianjin Capital Environmental Protection Group Company Limited
F:TIA
|
0.074x |
|
Profile Systems & Software SA
AT:PROF
|
0.011x |
|
Bougainville Copper Ltd
AU:BOC
|
-0.034x |
|
GENOR BIOPHARMA DL-00002
F:67N0
|
N/A |
|
Stereotaxis Inc
NYSE MKT:STXS
|
-0.364x |
Annual Cash Flow Conversion Efficiency for Surgical Science Sweden AB (2015–2024)
The table below shows the annual cash flow conversion efficiency of Surgical Science Sweden AB from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Surgical Science Sweden AB worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr4.83 Billion ≈ $519.64 Million |
Skr137.22 Million ≈ $14.77 Million |
0.028x | -48.18% |
| 2023-12-31 | Skr4.35 Billion ≈ $467.61 Million |
Skr238.29 Million ≈ $25.64 Million |
0.055x | +79.42% |
| 2022-12-31 | Skr4.24 Billion ≈ $455.91 Million |
Skr129.49 Million ≈ $13.93 Million |
0.031x | +180.37% |
| 2021-12-31 | Skr3.59 Billion ≈ $385.81 Million |
Skr39.08 Million ≈ $4.21 Million |
0.011x | -79.95% |
| 2020-12-31 | Skr427.05 Million ≈ $45.96 Million |
Skr23.23 Million ≈ $2.50 Million |
0.054x | -60.43% |
| 2019-12-31 | Skr401.68 Million ≈ $43.23 Million |
Skr55.20 Million ≈ $5.94 Million |
0.137x | +58.62% |
| 2018-12-31 | Skr79.38 Million ≈ $8.54 Million |
Skr6.88 Million ≈ $740.18K |
0.087x | -6.64% |
| 2017-12-31 | Skr85.52 Million ≈ $9.20 Million |
Skr7.94 Million ≈ $854.15K |
0.093x | -84.49% |
| 2016-12-31 | Skr22.40 Million ≈ $2.41 Million |
Skr13.40 Million ≈ $1.44 Million |
0.598x | +56.33% |
| 2015-12-31 | Skr19.60 Million ≈ $2.11 Million |
Skr7.50 Million ≈ $807.12K |
0.383x | -- |
About Surgical Science Sweden AB
Surgical Science Sweden AB (publ) develops and markets virtual reality simulators for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator … Read more